Aura Biosciences 3Q 2026: EPS ($0.29) — 10-Q Summary
Aura Biosciences reported a wider net loss in Q3 2026, with increased R&D and G&A expenses offsetting higher interest income. The loss per share narrowed to $0.29. The CoMpass trial enrollment is complete, and topline data is expected in 2H 2027. The company also reported interim data for NMIBC treatment and completed a restructuring.
How this was made
The 30-second read
Why it matters
The earnings miss and higher R&D spend suggest near‑term price pressure, while trial enrollment completion may set up future upside.
Market read
First‑time disclosure of Q3 results for a micro‑cap biotech, relevant for short‑term traders and long‑term investors monitoring trial milestones.
What to watch
Potential upside from upcoming 15‑month primary endpoint data in H2 2027 could offset near‑term earnings weakness.
Background
Aura Biosciences filed its Q3 2026 10‑Q, reporting widened net loss and progress on its Phase 3 CoMpass trial.
Ticker impact
Q3 2026 net loss widened to $32.07M (EPS -$0.29) and Phase 3 CoMpass trial enrollment completed.
downward pressure as investors digest widened loss and increased expenses
The loss exceeds prior quarter and R&D costs rose, suggesting short‑term downside risk.
Market effects
Biotech sector may see broader scrutiny of late‑stage trial costs.
U.S. biotech investors may adjust exposure to early‑stage loss makers.
Limited to investors tracking clinical‑trial driven biotech stocks.
Counterpoint
Long‑term investors might view the trial enrollment completion as a catalyst for future upside despite short‑term loss.
Key entities
- companyAura Biosciences, Inc.
Biotech firm developing oncology therapies.
